Sonoma Pharmaceuticals, Inc. (SNOA)
USD 2.45
(6.99%)
USD 2.45
(6.99%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -4.52 Million USD | -1.8% |
| 2023 | -4.44 Million USD | 32.37% |
| 2022 | -5.7 Million USD | -73.0% |
| 2021 | -3.22 Million USD | 37.39% |
| 2020 | -3.21 Million USD | 44.09% |
| 2019 | -10.85 Million USD | 24.03% |
| 2018 | -13.79 Million USD | -10.32% |
| 2017 | -12.68 Million USD | -27.61% |
| 2016 | -14.47 Million USD | -52.45% |
| 2015 | -7.94 Million USD | -10.05% |
| 2014 | -5.76 Million USD | -79.69% |
| 2013 | -4.05 Million USD | 45.75% |
| 2012 | -6.07 Million USD | 12.22% |
| 2011 | -7.14 Million USD | 9.44% |
| 2010 | -7.79 Million USD | 52.61% |
| 2009 | -16.45 Million USD | 31.8% |
| 2008 | -22.42 Million USD | -26.1% |
| 2007 | -18.81 Million USD | 3.36% |
| 2006 | -20.2 Million USD | -23.71% |
| 2005 | -15.87 Million USD | -1876.5% |
| 2004 | 902 Thousand USD | 161.61% |
| 2003 | -1.46 Million USD | -869.54% |
| 2002 | -151 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -799 Thousand USD | 31.3% |
| 2024 Q1 | -1.19 Million USD | -7.37% |
| 2024 Q2 | -1.16 Million USD | 2.68% |
| 2024 FY | - USD | -1.78% |
| 2024 Q4 | -1.36 Million USD | -71.21% |
| 2023 Q2 | -703 Thousand USD | 14.68% |
| 2023 Q1 | -824 Thousand USD | 77.93% |
| 2023 Q4 | -1.11 Million USD | 38.27% |
| 2023 FY | - USD | 32.37% |
| 2023 Q3 | -1.8 Million USD | -156.47% |
| 2022 Q2 | -1.06 Million USD | -24.07% |
| 2022 Q4 | -3.73 Million USD | -305.43% |
| 2022 FY | - USD | -73.0% |
| 2022 Q1 | -856 Thousand USD | 68.05% |
| 2022 Q3 | -921 Thousand USD | 13.28% |
| 2021 Q2 | 154 Thousand USD | 805.88% |
| 2021 FY | - USD | 37.39% |
| 2021 Q1 | 17 Thousand USD | 100.76% |
| 2021 Q4 | -2.67 Million USD | -391.56% |
| 2021 Q3 | -545 Thousand USD | -453.9% |
| 2020 Q2 | -1.13 Million USD | 32.2% |
| 2020 FY | - USD | 44.09% |
| 2020 Q3 | -1.01 Million USD | 10.41% |
| 2020 Q4 | -2.25 Million USD | -121.67% |
| 2020 Q1 | -1.67 Million USD | 36.97% |
| 2019 Q2 | -2.69 Million USD | 18.92% |
| 2019 Q3 | -2.18 Million USD | 19.07% |
| 2019 Q1 | -3.32 Million USD | 30.06% |
| 2019 Q4 | -2.65 Million USD | -21.49% |
| 2019 FY | - USD | 24.03% |
| 2018 Q3 | -3.18 Million USD | -12.22% |
| 2018 FY | - USD | -10.32% |
| 2018 Q4 | -4.75 Million USD | -49.22% |
| 2018 Q2 | -2.83 Million USD | 11.86% |
| 2018 Q1 | -3.22 Million USD | -11.15% |
| 2017 Q3 | -3.55 Million USD | -83.55% |
| 2017 Q4 | -2.89 Million USD | 18.57% |
| 2017 Q1 | -2.57 Million USD | 10.08% |
| 2017 FY | - USD | -27.61% |
| 2017 Q2 | -1.93 Million USD | 24.55% |
| 2016 Q3 | -3.12 Million USD | -68.23% |
| 2016 FY | - USD | -52.45% |
| 2016 Q2 | -1.85 Million USD | 19.65% |
| 2016 Q1 | -2.31 Million USD | -39.89% |
| 2016 Q4 | -2.85 Million USD | 8.51% |
| 2015 Q4 | -1.65 Million USD | 11.04% |
| 2015 Q3 | -1.85 Million USD | -23.22% |
| 2015 Q2 | -1.5 Million USD | 0.46% |
| 2015 Q1 | -1.51 Million USD | 28.18% |
| 2015 FY | - USD | -10.05% |
| 2014 Q3 | -1.56 Million USD | -20.09% |
| 2014 Q4 | -2.1 Million USD | -35.13% |
| 2014 FY | - USD | -79.69% |
| 2014 Q2 | -1.29 Million USD | -15.47% |
| 2014 Q1 | -1.12 Million USD | 18.36% |
| 2013 Q2 | -394 Thousand USD | 76.11% |
| 2013 FY | - USD | 45.75% |
| 2013 Q3 | -628 Thousand USD | -59.39% |
| 2013 Q1 | -1.64 Million USD | -21.25% |
| 2013 Q4 | -1.37 Million USD | -119.43% |
| 2012 Q1 | -1.93 Million USD | -73.9% |
| 2012 Q3 | -2.34 Million USD | -312.87% |
| 2012 FY | - USD | 12.22% |
| 2012 Q4 | -1.36 Million USD | 41.91% |
| 2012 Q2 | -567 Thousand USD | 70.76% |
| 2011 Q2 | -1.63 Million USD | 31.21% |
| 2011 Q3 | -1.93 Million USD | -18.19% |
| 2011 Q4 | -1.11 Million USD | 42.41% |
| 2011 FY | - USD | 9.44% |
| 2011 Q1 | -2.38 Million USD | -75.59% |
| 2010 Q3 | -2.57 Million USD | -2.59% |
| 2010 Q2 | -2.5 Million USD | -166.31% |
| 2010 FY | - USD | 52.61% |
| 2010 Q1 | -941 Thousand USD | 55.82% |
| 2010 Q4 | -1.35 Million USD | 47.26% |
| 2009 Q4 | -2.13 Million USD | 26.12% |
| 2009 Q3 | -2.88 Million USD | 53.81% |
| 2009 Q2 | -6.24 Million USD | -30.37% |
| 2009 Q1 | -4.78 Million USD | 31.45% |
| 2009 FY | - USD | 31.8% |
| 2008 FY | - USD | -26.1% |
| 2008 Q2 | -5.73 Million USD | 0.81% |
| 2008 Q1 | -5.78 Million USD | -9.39% |
| 2008 Q3 | -5.66 Million USD | 1.26% |
| 2008 Q4 | -6.98 Million USD | -23.35% |
| 2007 Q3 | -5.51 Million USD | -26.89% |
| 2007 Q1 | 1.16 Million USD | 105.14% |
| 2007 Q4 | -5.28 Million USD | 4.14% |
| 2007 FY | - USD | 3.36% |
| 2007 Q2 | -4.34 Million USD | -472.88% |
| 2006 Q2 | 541 Thousand USD | 0.0% |
| 2006 Q3 | 751 Thousand USD | 38.82% |
| 2006 Q4 | -22.68 Million USD | -3120.51% |
| 2006 FY | - USD | -23.71% |
| 2006 Q1 | 541 Thousand USD | 103.12% |
| 2005 Q2 | 339 Thousand USD | 0.0% |
| 2005 Q3 | 339 Thousand USD | 0.0% |
| 2005 FY | - USD | -1876.5% |
| 2005 Q1 | 339 Thousand USD | 0.0% |
| 2005 Q4 | -17.32 Million USD | -5211.8% |
| 2004 FY | - USD | 161.61% |
| 2003 FY | - USD | -869.54% |
| 2002 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 101.468% |
| Embecta Corp. | 245.4 Million USD | 101.844% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 104.139% |
| Dynavax Technologies Corporation | 9.66 Million USD | 146.814% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 96.986% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 102.778% |
| PainReform Ltd. | -9.56 Million USD | 52.712% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | 482.826% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -18.319% |
| SCYNEXIS, Inc. | 73.47 Million USD | 106.158% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | -92.47% |
| Cosmos Health Inc. | -17.06 Million USD | 73.479% |
| Journey Medical Corporation | 1.92 Million USD | 335.554% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -18.319% |
| Safety Shot Inc | -12.18 Million USD | 62.865% |
| Alpha Teknova, Inc. | -25.53 Million USD | 82.282% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 97.151% |
| Bright Green Corporation | - USD | Infinity% |
| Procaps Group, S.A. | 104.02 Million USD | 104.35% |
| Theratechnologies Inc. | -10.31 Million USD | 56.122% |
| Harrow Health, Inc. | 9.72 Million USD | 146.539% |
| Biofrontera Inc. | -18.45 Million USD | 75.478% |
| DURECT Corporation | -24.68 Million USD | 81.668% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 104.605% |
| Cronos Group Inc. | -72.14 Million USD | 93.728% |
| OptiNose, Inc. | -15.55 Million USD | 70.906% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 99.511% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 87.459% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 117.228% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 112.559% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | -15.364% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | -536.562% |
| Radius Health, Inc. | 38.31 Million USD | 111.812% |
| Universe Pharmaceuticals INC | -3.21 Million USD | -40.743% |
| ProPhase Labs, Inc. | -14.82 Million USD | 69.481% |
| Phibro Animal Health Corporation | 84.6 Million USD | 105.348% |
| Procaps Group S.A. | 104.02 Million USD | 104.35% |
| Alvotech | -484.86 Million USD | 99.067% |
| TherapeuticsMD, Inc. | -8.4 Million USD | 46.137% |
| Viatris Inc. | 3.51 Billion USD | 100.129% |
| Rockwell Medical, Inc. | -4.69 Million USD | 3.6% |
| Aytu BioPharma, Inc. | -1.01 Million USD | -347.134% |
| SIGA Technologies, Inc. | 84.15 Million USD | 105.377% |
| Tilray Brands, Inc. | -72.84 Million USD | 93.788% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | 657.266% |
| Shineco, Inc. | -26.55 Million USD | 82.959% |
| PetIQ, Inc. | 81.48 Million USD | 105.553% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | -25.082% |
| Incannex Healthcare Limited | -18.5 Million USD | 75.546% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 101.087% |
| Alimera Sciences, Inc. | 7.27 Million USD | 162.191% |
| Silver Spike Investment Corp. | 7.34 Million USD | 161.648% |
| Assertio Holdings, Inc. | -222.44 Million USD | 97.966% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | -13.39% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | -7.434% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | 73.072% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 77.41% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 96.966% |
| Hempacco Co., Inc. | -12.77 Million USD | 64.574% |
| Talphera, Inc. | -9.84 Million USD | 54.024% |
| Alvotech | -484.86 Million USD | 99.067% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | 105.839% |
| Lantheus Holdings, Inc. | 491 Million USD | 100.922% |
| Currenc Group, Inc. | -1.9 Million USD | -138.086% |
| Kamada Ltd. | 21.53 Million USD | 121.013% |
| Indivior PLC | 66 Million USD | 106.856% |
| Evoke Pharma, Inc. | -7.29 Million USD | 37.948% |
| Flora Growth Corp. | -45.87 Million USD | 90.135% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 77.41% |
| Evolus, Inc. | -41.81 Million USD | 89.177% |
| HUTCHMED (China) Limited | 25.52 Million USD | 117.726% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 101.874% |
| Akanda Corp. | -27.73 Million USD | 83.685% |